依达拉奉的应用及其与脑梗死患者一种新临床综合征的潜在关联：三例病例报告
Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports.
作者信息
Yang Liu, Xu Xin, Wang Liang, Zeng Ke-Bin, Wang Xue-Feng
机构信息
Department of Neurology, Central Hospital Affiliated to Chongqing University, Chongqing 400010, China.
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
出版信息
World J Clin Cases. 2023 Jul 6;11(19):4648-4654. doi: 10.12998/wjcc.v11.i19.4648.
BACKGROUND
Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.
CASE SUMMARY
We treated three patients with acute cerebral infarction who died following treatment with edaravone. Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.
CONCLUSION
Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions. Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction, clinicians' knowledge is the key element in recognizing this phenomenon.
背景
依达拉奉是治疗脑梗死患者的常用药物，在大多数情况下，依达拉奉引起的副作用较轻。然而，与依达拉奉相关的不良反应日益受到关注。
病例总结
我们治疗了3例急性脑梗死患者，他们在接受依达拉奉治疗后死亡。依达拉奉是治疗脑梗死患者的常用药物，在大多数情况下，依达拉奉引起的副作用较轻。然而，与依达拉奉相关的不良反应日益受到关注。
结论
我们的病例强调了对临床医生进行教育的重要性，使他们了解依达拉奉诱发的脑梗死新临床综合征可能是致命的药物不良反应。鉴于目前尚无实验室检查或确诊试验来诊断依达拉奉诱发的脑梗死死亡，临床医生的认知是识别这一现象的关键因素。
Zotero 插件